WO1991010722A3 - Immunoglobuline chimerique pour recepteurs de cd4 - Google Patents

Immunoglobuline chimerique pour recepteurs de cd4 Download PDF

Info

Publication number
WO1991010722A3
WO1991010722A3 PCT/US1990/007671 US9007671W WO9110722A3 WO 1991010722 A3 WO1991010722 A3 WO 1991010722A3 US 9007671 W US9007671 W US 9007671W WO 9110722 A3 WO9110722 A3 WO 9110722A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptors
chimeric immunoglobulin
receptor
human origin
antibodies
Prior art date
Application number
PCT/US1990/007671
Other languages
English (en)
Other versions
WO1991010722A2 (fr
Inventor
John Ghrayeb
David M Knight
James E Looney
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23816533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1991010722(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centocor Inc filed Critical Centocor Inc
Priority to DE69028713T priority Critical patent/DE69028713T3/de
Priority to CA002070182A priority patent/CA2070182C/fr
Priority to JP91504098A priority patent/JPH05502586A/ja
Priority to EP91903980A priority patent/EP0511308B2/fr
Publication of WO1991010722A2 publication Critical patent/WO1991010722A2/fr
Publication of WO1991010722A3 publication Critical patent/WO1991010722A3/fr
Priority to US09/896,050 priority patent/US7037496B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticorps chimériques pour récepteur de CD4, comprenant une région de liaison variable ou antigénique d'une origine non humaine spécifique au récepteur de CD4, ainsi qu'une région constante d'origine humaine. Ces anticorps sont utiles en tant qu'agents thérapeutiques pour des troubles auto-immuns.
PCT/US1990/007671 1989-12-27 1990-12-27 Immunoglobuline chimerique pour recepteurs de cd4 WO1991010722A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69028713T DE69028713T3 (de) 1989-12-27 1990-12-27 Schimäre immunoglobuline für cd4-rezeptoren
CA002070182A CA2070182C (fr) 1989-12-27 1990-12-27 Immunoglobuline chimerique pour recepteurs cda
JP91504098A JPH05502586A (ja) 1989-12-27 1990-12-27 Ｃｄ４受容体に対するキメラ免疫グロブリン
EP91903980A EP0511308B2 (fr) 1989-12-27 1990-12-27 Immunoglobuline chimerique pour recepteurs de cd4
US09/896,050 US7037496B2 (en) 1989-12-27 2001-06-29 Chimeric immunoglobulin for CD4 receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45738989A 1989-12-27 1989-12-27
US457,389 1989-12-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US45738989A Continuation-In-Part 1989-12-27 1989-12-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US07867100 A-371-Of-International 1992-06-25
US09/896,050 Continuation US7037496B2 (en) 1989-12-27 2001-06-29 Chimeric immunoglobulin for CD4 receptors

Publications (2)

Publication Number Publication Date
WO1991010722A2 WO1991010722A2 (fr) 1991-07-25
WO1991010722A3 true WO1991010722A3 (fr) 1991-09-05

Family

ID=23816533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/007671 WO1991010722A2 (fr) 1989-12-27 1990-12-27 Immunoglobuline chimerique pour recepteurs de cd4

Country Status (6)

Country Link
EP (1) EP0511308B2 (fr)
JP (1) JPH05502586A (fr)
AT (1) ATE143377T1 (fr)
CA (1) CA2070182C (fr)
DE (1) DE69028713T3 (fr)
WO (1) WO1991010722A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
CA2120911A1 (fr) * 1991-10-15 1993-04-29 Geoffrey Hale Medicaments
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
ATE367827T1 (de) * 1992-11-16 2007-08-15 Centocor Inc Verfahren zur reduzierung der immunogenizität der variablen regionen von antikörpern
HUT77342A (hu) * 1994-12-07 1998-03-30 F.Hoffmann-La Roche Ag. Immunoszupresszív aktivitással rendelkező monoklonális antitest fragmensek
AU2003213963A1 (en) * 2002-04-08 2003-10-27 The John P. Robarts Research Institute Method of treating or preventing autoimmune disease
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
CN113045661B (zh) * 2021-04-07 2022-06-21 中美冠科生物技术（太仓）有限公司 新型抗cd4抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009181A2 (fr) * 1987-05-29 1988-12-01 Tanox Biosystems, Inc. Anticorps monoclonaux neutralisant le hiv-1
EP0394827A1 (fr) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
WO1990012868A1 (fr) * 1989-04-25 1990-11-01 Tanox Biosystems, Inc. Anticorps specifiques contre le domaine de liaison de cd4 du virus d'immunodeficience humaine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009181A2 (fr) * 1987-05-29 1988-12-01 Tanox Biosystems, Inc. Anticorps monoclonaux neutralisant le hiv-1
WO1990012868A1 (fr) * 1989-04-25 1990-11-01 Tanox Biosystems, Inc. Anticorps specifiques contre le domaine de liaison de cd4 du virus d'immunodeficience humaine
EP0394827A1 (fr) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline

Also Published As

Publication number Publication date
EP0511308B2 (fr) 2003-07-09
ATE143377T1 (de) 1996-10-15
EP0511308A1 (fr) 1992-11-04
DE69028713T2 (de) 1997-02-06
CA2070182A1 (fr) 1991-06-28
DE69028713D1 (de) 1996-10-31
WO1991010722A2 (fr) 1991-07-25
DE69028713T3 (de) 2004-05-13
CA2070182C (fr) 2002-12-24
JPH05502586A (ja) 1993-05-13
EP0511308B1 (fr) 1996-09-25

Similar Documents

Publication Publication Date Title
AU1914795A (en) Monoclonal antibodies specific to vegf receptors and uses thereof
DE69221147T2 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
HK49497A (en) Antibody to human interleukin-6 receptor
EP0812333A4 (fr) Anticorps bispecifique efficace dans le traitement des lymphomes malins a cellules b et lignee cellulaire
EP0603735A3 (en) Monoclonal antibodies that define a unique antigen of human b-cell antigen receptor complex.
IL89489A0 (en) Chimeric antibodies directed against human carcinoembryonic antigen
AP9801209A0 (en) Recombinant anti-CD4 antibodies for human therapy
IL122423A0 (en) Therapeutic compounds comprised of anti-fc receptor antibodies
EP0743856A4 (fr) Heteropolymeres a base d'antigene utilises dans un procede de traitement de maladies autoimmunes
EP0809806A4 (fr) Anticorps monoclonaux contre des antigenes de surface de cellules osteogenes
AU629135B2 (en) Monoclonal antibody against melanoma
WO1991010722A3 (fr) Immunoglobuline chimerique pour recepteurs de cd4
GB2186592B (en) Cross-protective human monoclonal antibody compositions
HK1025500A1 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
MY107079A (en) Method of reducing immunoglobulin e responses
GB8910263D0 (en) Monoclonal antibodies specific for an immunoglobulin isotype
AU6036690A (en) Human monoclonal antibodies to hiv-1mn gp 120
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
WO1987007302A3 (fr) ANTICORPS MONOCLONAUX DES RECEPTEURS IgE DES LYMPHOCYTES HUMAINS, HYBRIDOMES PRODUISANT DE TELS ANTICORPS, ET KITS POUR UTILISER CES ANTICORPS
EP0289252A3 (en) Anti-t cell receptor, y-chain monoclonal antibody
ZA924068B (en) Monoclonal antibodies and antigen for human melanoma
HU895916D0 (en) Process for the preparation of monoclonal antibody recognaizing reg protein
AU4668889A (en) Monoclonal antibodies specific for tumor antigens
CS347190A3 (en) Murine lymphocyte hybridoma tsh-116 producing monoclonal antibody of the class igg 2a against human thyrostimulative hormone
CS347090A3 (en) Murine lymphocyte hybridoma tsh-51 producing monoclonal antibody of the class igg 2a against human thyrostimulative hormone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2070182

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991903980

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991903980

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991903980

Country of ref document: EP